Monte Rosa Therapeutics, Inc. GLUE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s total current liabilities?
- Monte Rosa Therapeutics, Inc. (GLUE) reported total current liabilities of $71.04M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s total current liabilities increased by 20.0% year-over-year, from $59.22M to $71.04M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s total current liabilities has grown at a 17.0% compound annual growth rate (CAGR), from $29.28M to $64.21M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.